Sotera Health drops 13% as analysts cut targets after earnings

SHC entered earnings week already under pressure. It left it 13% lighter, with two firms marking down their targets on Wednesday morning and short sellers quietly adding to positions they began rebuilding a month ago.

The catalyst was the Q3 print itself. The stock shed nearly 10% on Tuesday and finished the week at $16.03. That extends a 12% decline over the past month and puts the shares well below the mean analyst price target of $22.17, a gap that reflects how sharply sentiment has deteriorated since the summer. JP Morgan's Casey Woodring moved within hours of the release, cutting his target to $15 from $17 while keeping an Underweight rating he initiated in mid-October. Barclays' Luke Sergott went the other way on direction but followed on magnitude, trimming his Overweight target to $20 from $22. The divergence between those two reads captures the split on the Street right now: bears think the stock is fairly valued at current levels, bulls think the sell-off is an overreaction to execution noise around a business that still generates 51%-plus EBITDA margins.

Positioning heading into the print was more nuanced than the price move suggests. Short interest has been climbing steadily, rising 35% in the past month to 5.8% of the free float. The rebuild began in earnest around October 8, when shorts added roughly 2.3 million shares in a single session, lifting the position from around 12.2 million shares to nearly 15 million within days. But the borrow market remains loose. Availability is at 1,144%, meaning there are more than eleven shares available to borrow for every one already shorted. Cost to borrow is a negligible 0.41%. This is a position being built by conviction, not squeezed in by scarcity. The options market adds little urgency: the put/call ratio of 0.0125 sits only modestly above its 20-day average of 0.011, and the z-score of 0.74 is nowhere near the kind of defensive extreme that would signal broad hedging demand. Options traders are not panicking into puts, which is a mild counterpoint to the narrative that the market is bracing for sustained deterioration.

The Street's debate maps reasonably neatly onto a valuation that has re-rated quickly. The EV/EBITDA multiple has compressed from roughly 10.4x a month ago to 9.7x now, a 7% contraction in 30 days. The PE has moved from 17.6x to 15.1x over the same stretch. The bull case, as articulated before this week's move, rested on consistent revenue beats across all three segments, Sterigenics growth from pricing and volume, and ongoing litigation de-risking after the New Mexico settlement. The bear case flagged exactly the kind of multiple compression that has since arrived, with peer group EV/EBITDA having already drifted from 12.5x to 12x. At 9.7x, the question now is whether SHC deserves a discount to peers and, if so, how wide. The earnings yield factor score ranks in the 90th percentile, suggesting the market is pricing in a meaningful risk premium relative to the company's earnings power.

Ownership tells a story of concentrated, mostly passive positions that have been building through the year. Sessa Capital and Darsana each hold roughly 9.5% and 9.5% of shares respectively, both disclosed under 13G filings rather than activist 13Ds, so neither has signalled an intention to push for strategic change. Warburg Pincus and GTCR, which together held over 22% as recently as September, have both exited entirely per their May filings. That unwinding of private equity anchor positions was a known technical overhang for most of the year. BlackRock has been moving the other way, lifting its stake from 6.2% to 8.4% across two filings. The insider register is less encouraging on a 90-day basis: open-market sales of roughly $21 million from Executive Chairman Michael Petras in August dominate the net, with no open-market purchases from any named insider in the past six months. The executive committee grants in May were compensation mechanics, not conviction buys.

Wikipedia attention for SHC jumped to a z-score of 4.5 relative to its own 90-day history as of mid-October, well before this week's move, suggesting retail attention was elevated heading into the print. What to watch now is whether the two post-earnings target cuts mark the beginning of a broader round of Street revisions, or whether the bulls at Barclays, Piper Sandler and Goldman Sachs hold their constructive stance after digesting the full Q3 detail.